Search - tctmd.com

Displaying 641 - 660 of 764

Sort: Relevancy | Date

Presentation TCTAP 2012

Everolimus-Eluting Stent Implantation for Unprotected Left Main Stenosis:

Presenter: Young-Hak Kim

April 26, 2012

News Daily News

Meta-Analysis: First-Gen DES Show Long-term Safety, Efficacy in STEMI Setting

L.A. McKeown

April 25, 2012

News Daily News

Meta Análisis: Los SLF de 1ª Generación se Muestran Seguros y Eficaces a Largo Plazo contra los STEMI

L.A. McKeown

April 25, 2012

Presentation Fellows 2012

Everolimus-Eluting Stents: Preclinical Foundation and Clinical Results

Presenter: Gregg Stone

April 21, 2012

News Daily News

First Implanted Biodegradable Stent Shows Positive Safety at 10 Years

Jason Kahn

April 17, 2012

News Daily News

El Primer Stent Biodegradable Implantado resulta Seguro a los 10 Años

Jason Kahn

April 17, 2012

News Industry News

Abbott Receives Approval for Next-Generation XIENCE PRIME™ Drug Eluting Stent in Japan

April 09, 2012

News Daily News

Se Publica el PRODIGY: No se observa Ventaja alguna a Largo Plazo con el Clopidogrel

April 03, 2012

News Daily News

PRODIGY Published: No Advantage to Long-term Clopidogrel

April 03, 2012

Presentation ACC 2012

Two-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents in De Novo Coronary Artery Lesions

Presenter: Gregg Stone

March 28, 2012

News Conference News ACC 2012

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

March 26, 2012

News Industry News

Boston Scientific Supports New Clinical Trial to Evaluate Platinum Chromium Coronary Stents in Treating Heart Attack Patients

March 26, 2012

News Daily News

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Caitlin E. Cox

March 25, 2012

News Daily News

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Caitlin E. Cox

March 25, 2012

News Conference News ACC 2012

Adjunctive Cilostazol Noninferior to Double-Dose Clopidogrel in All-Comer PCI Trial

L.A. McKeown

March 25, 2012

News Conference News ACC 2012

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Jason Kahn

March 24, 2012

News Industry News

Boston Scientific Announces New Clinical Data to be Presented at ACC 2012 on the Market-Leading PROMUS Element™ Stent

March 20, 2012

News Industry News

Abbott Reinforces Global Vascular Leadership with New Data on Innovative Technologies at ACC 2012

March 20, 2012

News Daily News

SES Effective for Both Focal, Diffuse DES Restenosis

March 13, 2012

News Daily News

El SLS es Efectivo contra la Reestenosis tanto Focal como Difusa del SLF

March 13, 2012

Advertisement

Everolimus-Eluting Stent Implantation for Unprotected Left Main Stenosis:

Meta-Analysis: First-Gen DES Show Long-term Safety, Efficacy in STEMI Setting

Meta Análisis: Los SLF de 1ª Generación se Muestran Seguros y Eficaces a Largo Plazo contra los STEMI

Everolimus-Eluting Stents: Preclinical Foundation and Clinical Results

First Implanted Biodegradable Stent Shows Positive Safety at 10 Years

El Primer Stent Biodegradable Implantado resulta Seguro a los 10 Años

Abbott Receives Approval for Next-Generation XIENCE PRIME™ Drug Eluting Stent in Japan

Se Publica el PRODIGY: No se observa Ventaja alguna a Largo Plazo con el Clopidogrel

PRODIGY Published: No Advantage to Long-term Clopidogrel

Two-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents in De Novo Coronary Artery Lesions

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

Boston Scientific Supports New Clinical Trial to Evaluate Platinum Chromium Coronary Stents in Treating Heart Attack Patients

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Adjunctive Cilostazol Noninferior to Double-Dose Clopidogrel in All-Comer PCI Trial

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Boston Scientific Announces New Clinical Data to be Presented at ACC 2012 on the Market-Leading PROMUS Element™ Stent

Abbott Reinforces Global Vascular Leadership with New Data on Innovative Technologies at ACC 2012

SES Effective for Both Focal, Diffuse DES Restenosis

El SLS es Efectivo contra la Reestenosis tanto Focal como Difusa del SLF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content